HK1083458A1 - Improved transdermal delivery system - Google Patents

Improved transdermal delivery system

Info

Publication number
HK1083458A1
HK1083458A1 HK06103512.7A HK06103512A HK1083458A1 HK 1083458 A1 HK1083458 A1 HK 1083458A1 HK 06103512 A HK06103512 A HK 06103512A HK 1083458 A1 HK1083458 A1 HK 1083458A1
Authority
HK
Hong Kong
Prior art keywords
functional drug
amine functional
matrix
drug
tds
Prior art date
Application number
HK06103512.7A
Other languages
English (en)
Inventor
Mike Hannay
Dietrich Wilhelm Schacht
Hans-Michael Wolff
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of HK1083458A1 publication Critical patent/HK1083458A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Feeding, Discharge, Calcimining, Fusing, And Gas-Generation Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK06103512.7A 2002-07-30 2006-03-20 Improved transdermal delivery system HK1083458A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02016864A EP1386604A1 (en) 2002-07-30 2002-07-30 Improved transdermal delivery system
PCT/EP2003/008319 WO2004012719A1 (en) 2002-07-30 2003-07-28 Improved transdermal delivery system

Publications (1)

Publication Number Publication Date
HK1083458A1 true HK1083458A1 (en) 2006-07-07

Family

ID=30011092

Family Applications (1)

Application Number Title Priority Date Filing Date
HK06103512.7A HK1083458A1 (en) 2002-07-30 2006-03-20 Improved transdermal delivery system

Country Status (22)

Country Link
EP (2) EP1386604A1 (xx)
JP (1) JP4837915B2 (xx)
KR (1) KR101016914B1 (xx)
CN (1) CN100558350C (xx)
AT (1) ATE343380T1 (xx)
AU (1) AU2003266252B2 (xx)
BR (1) BR0313092A (xx)
CA (1) CA2490573C (xx)
CY (1) CY1105878T1 (xx)
DE (1) DE60309329T2 (xx)
DK (1) DK1524971T3 (xx)
ES (1) ES2273042T3 (xx)
HK (1) HK1083458A1 (xx)
IL (1) IL165917A (xx)
MX (1) MXPA05000349A (xx)
NO (1) NO334187B1 (xx)
NZ (1) NZ537476A (xx)
PL (1) PL376999A1 (xx)
PT (1) PT1524971E (xx)
SI (1) SI1524971T1 (xx)
WO (1) WO2004012719A1 (xx)
ZA (1) ZA200500255B (xx)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine
DE10361258A1 (de) 2003-12-24 2005-07-28 Schwarz Pharma Ag Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson
DE102004014841B4 (de) 2004-03-24 2006-07-06 Schwarz Pharma Ag Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms
US9155725B2 (en) 2008-02-27 2015-10-13 Hisamitsu Pharmaceutical Co., Inc. Adhesive skin patch and packaged product
EP2255809B1 (en) * 2008-02-27 2017-08-23 Hisamitsu Pharmaceutical Co., Inc. Medicated patch
EA025584B1 (ru) * 2009-12-22 2017-01-30 ЮСиБи ФАРМА ГМБХ Поливинилпирролидон для стабилизации твердой дисперсии некристаллической формы ротиготина
DE102011090178A1 (de) 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
WO2015001012A1 (de) 2013-07-03 2015-01-08 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches system mit elektronischem bauteil
WO2015177204A1 (en) 2014-05-20 2015-11-26 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system containing rotigotine
US11752110B2 (en) 2014-05-20 2023-09-12 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system including an interface mediator
EP3145503A1 (en) 2014-05-20 2017-03-29 LTS Lohmann Therapie-Systeme AG Method for adjusting the release of active agent in a transdermal delivery system
ES2966170T3 (es) 2020-01-24 2024-04-18 Luye Pharma Switzerland Ag Sistema terapéutico transdérmico que comprende rotigotina y al menos un adhesivo de silicona no resistente a las aminas
EP3949956A1 (en) * 2020-08-06 2022-02-09 LTS Lohmann Therapie-Systeme AG Esketamine-suspension-tts

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5736577A (en) * 1995-01-31 1998-04-07 Sepracor, Inc. Methods and compositions for treating urinary incontinence using optically pure (S)-oxybutynin
US5989586A (en) * 1992-10-05 1999-11-23 Cygnus, Inc. Two-phase matrix for sustained release drug delivery device
US5601839A (en) * 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE19814083C2 (de) * 1998-03-30 2002-02-07 Lohmann Therapie Syst Lts Verfahren zur Herstellung von transdermalen therapeutischen Systemen unter Verwendung von basischen Alkalimetallsalzen zur Umwandlung von Wirkstoffsalzen in die freien Basen
FR2792529B1 (fr) * 1999-04-26 2001-09-28 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines
IT1311696B1 (it) * 1999-06-22 2002-03-19 Zanussi Elettromecc Compressore del fluido frigorigeno azionato da un motore elettricoa frequenza di alimentazione variabile
JP2002045699A (ja) * 2000-08-08 2002-02-12 Mitsubishi Electric Corp 排ガス浄化用層状電気化学触媒
US20020119187A1 (en) * 2000-09-29 2002-08-29 Cantor Adam S. Composition for the transdermal delivery of fentanyl
DE10060550C1 (de) * 2000-12-06 2002-04-18 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Oxybutynin und Verfahren zur Herstellung Oxybutynin enthaltender Wirkstoffschichten
CA2440884C (en) * 2001-03-16 2012-05-22 Alza Corporation Transdermal patch for administering fentanyl
US20030157166A1 (en) * 2001-03-16 2003-08-21 Chen Chih Ming Controlled release sulfonylurea formulation
ES2203563T3 (es) * 2001-05-08 2004-04-16 Schwarz Pharma Ag Sistema terapeutico transdermico mejorado para el tratamiento de la enfermedad de parkinson.
EP1386605A1 (en) * 2002-07-30 2004-02-04 Schwarz Pharma Ag Improved transdermal delivery system for the administration of rotigotine

Also Published As

Publication number Publication date
DE60309329T2 (de) 2008-04-17
BR0313092A (pt) 2005-06-21
NO334187B1 (no) 2014-01-13
SI1524971T1 (sl) 2007-02-28
PL376999A1 (pl) 2006-01-23
DE60309329D1 (de) 2006-12-07
IL165917A0 (en) 2006-01-15
EP1524971A1 (en) 2005-04-27
IL165917A (en) 2007-07-24
PT1524971E (pt) 2007-01-31
CN1671365A (zh) 2005-09-21
CY1105878T1 (el) 2011-02-02
EP1386604A1 (en) 2004-02-04
CA2490573A1 (en) 2004-02-12
ATE343380T1 (de) 2006-11-15
NZ537476A (en) 2007-08-31
JP2005535686A (ja) 2005-11-24
JP4837915B2 (ja) 2011-12-14
KR101016914B1 (ko) 2011-02-22
WO2004012719A1 (en) 2004-02-12
DK1524971T3 (da) 2007-02-19
KR20050025638A (ko) 2005-03-14
EP1524971B1 (en) 2006-10-25
CN100558350C (zh) 2009-11-11
CA2490573C (en) 2011-06-07
ES2273042T3 (es) 2007-05-01
ZA200500255B (en) 2006-01-25
MXPA05000349A (es) 2005-03-31
AU2003266252B2 (en) 2008-11-20
AU2003266252A1 (en) 2004-02-23
NO20050770L (no) 2005-02-11

Similar Documents

Publication Publication Date Title
HK1083458A1 (en) Improved transdermal delivery system
NO20050472L (no) Forbedret transdermalt leveringssystem for administrering av rotigotin
TW570815B (en) Transdermal therapeutic system (TTS) containing the active substance fentanyl
MXPA04001676A (es) Sistema terapeutico transdermico con fentanilo o sustancias relacionadas.
MY105347A (en) Transdermal therapeutic system comprising as active component buprenorphine
NO20001003D0 (no) Transdermalt terapeutisk system omfattende et trykksensitivt adhesivt reservoarsjikt og et unidireksjonalt elastisk dekksjikt
WO2001068060A3 (de) Stabilisierte übersättigte transdermale therapeutische matrixsysteme
DK1143938T3 (da) Transdermalt terapeutisk system med en selvklæbende matrix, der indeholder organiske syreadditionssalte af alkaloider af morphin- eller morphin-type
MY110391A (en) Nitroglycerin-containing patch, a process for the production and the use thereof
ATE252904T1 (de) Transdermales therapeutisches system zur verabreichung von zaleplon
PL339226A1 (en) Transdermal therapeutic system containing scopolamine in the form of base as its active substance
DE20221160U1 (de) Transdermales therapeutisches System mit Fentanyl bzw. verwandten Substanzen

Legal Events

Date Code Title Description
PE Patent expired

Effective date: 20230727